Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.50 |
| ▸ | RELA | Q04206 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | USP7 | Q93009 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 2/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21937449 | 0.83 | MCHR1 (0.60) | SMN1; SMN2ALDH1A1NPC1KDM4EHPGD | |
| SCHEMBL31035573 | 0.78 | PARP1 (0.36) | SMN1; SMN2ALDH1A1NPC1KDM4EHPGD | |
| SCHEMBL3340576 | 0.77 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1NPC1KDM4EHPGD | |
| SCHEMBL31035662 | 0.77 | APP (0.43) | SMN1; SMN2ALDH1A1NPC1RAB9ASCN10A | |
| SCHEMBL22277247 | 0.76 | MCHR1 (0.45) | SMN1; SMN2ALDH1A1NPC1KDM4EHPGD | |
| SCHEMBL31035796 | 0.75 | NPC1 (0.50) | SMN1; SMN2ALDH1A1NPC1KDM4EHPGD | |
| SCHEMBL8814197 | 0.74 | MCHR1 (0.57) | SMN1; SMN2ALDH1A1NPC1KDM4EHPGD | |
| SCHEMBL12778283 | 0.74 | KDM4E (0.54) | SMN1; SMN2ALDH1A1NPC1KDM4EHPGD | |
| SCHEMBL16648467 | 0.74 | KDM4E (0.54) | SMN1; SMN2ALDH1A1NPC1KDM4EHPGD | |
| SCHEMBL19086907 | 0.74 | KDM4E (0.54) | SMN1; SMN2ALDH1A1NPC1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376473-A1 | PRMTS INHIBITOR AND USE THEREOF | CYTOSINLAB THERAPEUTICS CO LTD (CN) | 2025-12-11 | — | — | US | disclosed |
| EP-4549440-A1 | CLASS OF PRMT5 INHIBITORS AND USE THEREOF | Cytosinlab Therapeutics Co., Ltd. (CN) | 2025-05-07 | — | — | EP | disclosed |
| EP-4549442-A1 | PRMT5 INHIBITORS AND USE THEREOF | Cytosinlab Therapeutics Co., Ltd. (CN) | 2025-05-07 | — | — | EP | disclosed |
| CN-119552175-B | PRMT5-MTA inhibitor | 赛岚(杭州)生物医药科技有限公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-119552175-A | PRMT5-MTA inhibitor | 赛岚(杭州)生物医药科技有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-119562954-A | PRMT5 inhibitor and application thereof | 上海赛岚生物科技有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-119487041-A | PRMT5 inhibitor and application thereof | 上海赛岚生物科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-117800991-B | PRMT5 inhibitor and application thereof | 赛岚(杭州)生物医药科技有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20240376126-A1 | PRMT5 INHIBITOR AND THE USE THEREOF | CYTOSINLAB THERAPEUTICS CO., LTD. (CN) | 2024-11-14 | — | — | US | disclosed |
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | SMN1; SMN2 1051/4885ALDH1A1 504/4885NPC1 902/4885 |
| US-20240376126-A1 | PRMT5 INHIBITOR AND THE USE THEREOF | PRMT5, PRMT1, PRMT6 | SMN1; SMN2 968/4885ALDH1A1 4208/4885NPC1 3221/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | SMN1; SMN2 1051/4885ALDH1A1 504/4885NPC1 902/4885 |
| US-20250376473-A1 | PRMTS INHIBITOR AND USE THEREOF | PRMT5, PRMT1, PRMT6 | SMN1; SMN2 1957/4885ALDH1A1 3032/4885NPC1 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.